Aimmune's PhIII peanut allergy study wows on the primary endpoint, setting up FDA pitch -- and shares slide
Four months after DBV Technologies stock was crushed by a shaky set of pivotal data for its peanut allergy drug, rival Aimmune Therapeutics $AIMT says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
